Logo Image
|Webcasts|October 31, 2019

Launching Medical Devices in the Japanese Market - How to navigate regulatory and reimbursement approval

Author(s)IQVIA

This webinar will provide an overview of the Japanese regulations and development in the Japanese market. Live: Thursday, Oct. 31, 2019 at 11am EDT On demand available after airing until Oct. 31, 2020 Register free

Register free: http://www.appliedclinicaltrialsonline.com/act_w/devices

Event Overview:
Approximately 10 years ago “Device Lag” was a major topic of discussion related to the Japanese regulatory environment. Currently, the Japanese government and the PMDA have improved their processes and “Device Lag” is no longer an issue. As a result, through good preparation it is now possible to launch medical devices in the Japanese market in a timely manner. You now have more control over how quickly your product is launched.

Japan has a universal health insurance system and the government determines reimbursement device and physician fees. Reimbursement will be based on the regulatory approval conditions; therefore, reimbursement strategy should be part of your overall business plan. Your goal should be receiving good reimbursement approval and a successful launch in the Japanese market and not simply regulatory approval.  

This webinar will provide an overview of the Japanese regulations and development in the Japanese market.     

Key Learning Objectives:

Overview of the Japanese:

Medical Device Market

Insurance System

Regulatory Environment

Speaker: Hiroshi Iwai, Regulatory Consultant, IQVIA Japan Group

Time and Date: Thursday, Oct. 31, 2019 at 11am EDT 

On demand available after airing until Oct. 31, 2020

Sponsor: IQVIA

Register free: http://www.appliedclinicaltrialsonline.com/act_w/devices

Related to this article

View more
The Human Side of Clinical Trials: How Measuring Readiness at Training Predicts Trial Risk Before It Shows Up in the Data
The Human Side of Clinical Trials: How Measuring Readiness at Training Predicts Trial Risk Before It Shows Up in the Data
This episode of The Human Side of Clinical Trials, hosted by Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., and Kelly Ritch, chief operating officer of ArcheMedX, Inc., explores why training completion metrics like attendance and quiz scores fail to capture true study readiness, and how measuring both competence and confidence can reveal trial risks before enrollment even begins.
Read more
What the Epilepsy Community Has Taught Us About Trial Feasibility
What the Epilepsy Community Has Taught Us About Trial Feasibility
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, shares what she has learned firsthand from families living with Dravet syndrome and CDKL5 deficiency disorder about what makes trial participation possible—and what makes it not.
Read more